• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Monoclonal antibodies for asthma and chronic obstructive pulmonary disease.
【24h】

Monoclonal antibodies for asthma and chronic obstructive pulmonary disease.

机译：哮喘和慢性阻塞性肺疾病的单克隆抗体。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: In asthma and chronic obstructive pulmonary disease (COPD), the inflammation in the airways cannot always be controlled with conventional therapies, such as inhaled corticosteroids. Addition of more specific anti-inflammatory therapies, such as monoclonal antibodies, against inflammation pathways might improve the disease outcome. AREAS COVERED: This review individually discusses the major inflammation pathways and their potential blocking monoclonal antibodies in asthma and COPD. EXPERT OPINION: The current use of omalizumab in asthma provides a good example on the potential therapeutic role of monoclonal antibodies in both asthma and COPD. There are many other monoclonal antibodies which are currently investigated as possible therapies in these diseases. The identification of the disease subsets in which such antibodies might exert the maximum benefit opens the door for personalized medicine and for targeted biological therapy in asthma and COPD.
机译：简介：在哮喘和慢性阻塞性肺疾病（COPD）中，气道中的炎症并不总是可以通过传统疗法（例如吸入皮质类固醇）来控制。增加针对炎症途径的更特异性的抗炎疗法，例如单克隆抗体，可能会改善疾病的预后。覆盖的区域：这篇综述单独讨论了哮喘和COPD中的主要炎症途径及其潜在的阻断性单克隆抗体。专家意见：omalizumab目前在哮喘中的使用为单克隆抗体在哮喘和COPD中的潜在治疗作用提供了一个很好的例子。目前还研究了许多其他单克隆抗体，作为这些疾病的可能疗法。对此类抗体可能发挥最大益处的疾病亚群的鉴定，为哮喘和COPD中的个性化药物和靶向生物治疗打开了大门。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号